Skip to product information
1 of 4

Vetilea Resolmega

Vetilea Resolmega

Regular price LOGIN TO SEE PRICING
Regular price LOGIN TO SEE PRICING Sale price LOGIN TO SEE PRICING
Sale Sold out
Taxes included.
Size

Designed to aid the body’s natural resolution of inflammatory processes. 

Vetilea resolmega are soft capsules containing Lipivet specialised Omega 3 fatty acids. Sourced from fish oil, rich in DHA, EPA and pro-resolvin mediators. 

To support the body’s nautral ability to resolve acute and chronic inflammatory processes. Useful in atopic dermatitis, osteoarthritis, chronic inflammatory disease and heart disease.

Vetilea Resolmega comes in a box of 60 soft gelatin capsules. 

  • Cat
  • Dog
View full details

calms itching sensitive skinn

Novel Mechanism: The TRPV1 antagonist

Vetilea Travaderm is a spray for topical use to soothe itching in sensitive and allergic skin in localized areas. It can be used in young animals, immunosuppressed animals, in chronic patients and as a complement to pharmacological antipruritic treatments.

Vetilea Travaderm contains Hydroxymethoxyiodobenzyl Glycoamide Pelargonate (HMBG) in a solution of emollient oils that help break the itch-scratch cycle.

The main component of Vetilea Travaderm works through a novel mechanism. It is a TRPV1 receptor antagonist (Transient Receptor Potential Vainilloid 1) that helps reduce neuronal stimulation of itching and interrupt the itch-scratch cycle.
In addition, it helps maintain the skin’s barrier function and reduce oxidative stress.

icon

Unique in the market

It is the first product that acts at the neuronal level to stop itching

icon

Exclusive format

60 ml bottle, topical spray for easy application on sensitive animal skins

Img

Preclinical Data

Several preclinical studies have been carried out to determine the mechanism of action of Hydroxymethoxyiodobenzyl glycoamide pelargonate.

TRPV1 antagonism
The modulatory activity of the TRPV1 channel was evaluated in neuroblastoma cells expressing this receptor. Capsaicin (10 µM) was used as the channel activator compound. The antagonist activity of the compound was demonstrated, with an IC50 of 19.90 µM.

img img

Figure 1.
Dose-dependent antagonist activity of HMBG (in publication AG1549), adapted from López-González et al .

Electrophysiological functional study of TRPV1
The transmission of current through the TRPV1 channel was studied in cells transfected with this channel.
HMBG was found to block capsaicin-initiated activity by applying the patch clamp technique in cells expressing the TRPV1 channel.

img img

Figure 2.
A) Representative currents in capsaicin control and HMBG treatment (AG1549 in publication)
B)% of current evoked with capsaicin in control group and with HMBG. Graph adapted from López-González et al .

In vitro toxicology
Irritation, cytotoxicity and skin sensitization, phototoxicity and mutagenesis studies have been carried out with satisfactory results.

The product should not be applied on open wounds, eyes or mucous membranes.

img

CLINICAL STUDY IN PODODERMATITIS
Study published in Veterinary Dermatology, demonstrates the effectiveness of Travaderm in pododermatitis

CLINICAL STUDY IN PODODERMATITIS

ALWAYS BY YOUR SIDE

The company loyal to the vet